Business Wire

XPENG To Attend IAA Mobility 2023 as EU Deliveries Begin

30.8.2023 13:45:00 EEST | Business Wire | Press release

Share

XPeng Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the beginning of P7 deliveries in four key European markets and its participation in IAA Mobility 2023, Munich, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830333578/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

European P7 Delivery

Outstanding Smart EVs for Europe

XPENG G9 and P7 were launched in February this year, with excitement around the brand and positive feedback continuing to build up with deliveries beginning.

In June, XPENG G9 broke the charging record at the two-day NAF (Norwegian Automobile Federation) and Motor EV Summer test, also known as El-Prix 2023, reaching a peak charging power of 319 kW. This also represented the test's highest average charging power at 212 kW, allowing drivers to charge up to 100 km of range in just five minutes. G9 and P7 occupied the top two spots in the range test, which measures the real-world deviation rate compared to the stated WLTP range; there was an increase of 13% and 10% for G9(4WD) and P7(4WD), respectively.

As a spacious sports sedan, XPENG P7's cabin provides exceptional comfort, which is surrounded by a sleek exterior epitomizing XPENG's Dynamic Aesthetics design language. Deliveries of P7 recently commenced, with the first batches of vehicles having arrived at XPENG's delivery centers in Lørenskog, Norway; Järfälla, Sweden; Hillerød, Denmark; and Badhoevedorp, The Netherlands.

"We’re delighted that customers who placed orders at the very beginning can finally drive P7 on Europe’s roads,” said Eric Xu, VP of International Markets XPENG. “The feedback has been positive so far, and with our rapidly growing network, we’re very optimistic about our future on the continent.”

Drive With Confidence

As part of the company's dedication to delivering superior customer experiences, XPENG is offering a comprehensive service agreement, which includes an eight-year warranty for the vehicle's battery, as well as a seven-year/160,000 km extended warranty for all orders placed in 2023.

Deliveries of G9 will begin in the coming months as XPENG's network of authorized agencies and partners expands, which will optimize sales, delivery, and servicing processes to create a seamless customer journey.

Learn More About XPENG P7 for Europe

https://www.heyxpeng.com/nl/p7

https://www.heyxpeng.com/dk/p7

https://www.heyxpeng.com/no/p7

https://www.heyxpeng.com/se/p7

XPENG at IAA Mobility 2023

As a technology pioneer in the mobility industry, XPENG will participate in the world's largest mobility event this year, IAA Mobility, on September 4–10, 2023 in Munich. XPENG's agenda is as follows:

  • Pre-IAA XPENG Press Conference
    • H4 Hotel Munich Messe
    • Monday, September 4, 11 am–12 pm
  • IAA Summit Panel: Unleashing the Integrated Smart Ecosystem
    • Blue Stage
    • A discussion on how intelligent and autonomous vehicles are transforming the industry and our overall mobility experience
    • Featuring Co-President and Vice Chairman Brian Gu
    • Tuesday, September 5, 3 pm–3:45 pm
  • Open Space Activation with Product Displays
    • Konigsplatz, Stand KP155
    • Tuesday, September 5 – Sunday, September 10, 10 am–8 pm
  • P7 and G9 Test Drives at Blue Lane*
    • Near Hall C3, Munich Messe
      • Monday, September 4, 8 am–6 pm
      • Tuesday, September 5 – Friday, September 8, 9 am–6 pm
    • Near Konigsplatz
      • Tuesday, September 5 – Saturday, September 9, 10 am–8 pm
      • Sunday, September 10, 10 am–5 pm

*Subject to pre-booking

Follow XPENG at IAA Mobility 2023

Instagram

LinkedIn

Twitter

Facebook

About XPENG

XPENG is a global smart electric vehicle company founded in 2014 in Guangzhou, China, developing clean, intuitive, and creative mobility solutions. With industry-leading R&D facilities, XPENG is bringing vehicles with superior safety, electric efficiency, and on-road performance to markets across the globe. The company is constantly working to advance its core technology offering, including autonomous driving capabilities, SEPA 2.0, and captivating in-car infotainment systems. XPENG has headquarters in Guangzhou and Amsterdam, with additional offices in Beijing, Shanghai, and Silicon Valley.

Visit heyxpeng.com for more information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Enquiries: pr@xiaopeng.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye